Form 8-K Amphastar Pharmaceutical For: Jul 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
FDA issues warning letter to Amphastar Pharma subsidiary over manufacturing
July 8, 2026 6:04 AM EDTAmphastar Pharmaceuticals (NASDAQ: AMPH) disclosed that its subsidiary, International Medication Systems, Limited (IMS), received a warning letter from the U.S. Food and Drug Administration on July 2, 2026, related to its drug manufacturing facility in South El Monte, California.
The warning letter follows an FDA inspection of the facility conducted in December 2025,... More
